NeuroPaceNPCE -3.93%65 3-Year RORE % is -19.85 as of Mar. 2026. GuruFocus rates NPCE with a GF Score™ of 65/100 and a GF Value™ of $11.41 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 782 Medical Devices & Instruments companies, NeuroPace ranks worse than 65.86% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
NeuroPace's 3-Year RORE % for the quarter that ended in Mar. 2026 was -19.85%.
The industry rank for NeuroPace's 3-Year RORE % or its related term are showing as below:
NPCE's 3-Year RORE % is ranked worse than 65.86% of 782
companies
in the Medical Devices & Instruments industry
Industry Median: -4.31
vs NPCE: -19.85
NeuroPace (NAS:NPCE) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
NeuroPace 3-Year RORE % Related Terms
NeuroPace 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for NeuroPace's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NPCE vs CLPT, CTKB, CERS: 3-Year RORE % Comparison
For the Medical Devices subindustry, NeuroPace's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where NeuroPace's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
NeuroPace (NPCE) has a 3-Year RORE % of -19.85 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on NeuroPace and its competitors. According to the industry distribution chart, NeuroPace ranks #515 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 65.9%.
Is NeuroPace's 3-Year RORE % too high?
NeuroPace's current 3-Year RORE % is -19.85. Based on the distribution chart, NeuroPace ranks #515 out of 782 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NeuroPace has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's 3-Year RORE % compare to CLPT and CTKB?
According to the Medical Devices & Instruments industry distribution chart, NeuroPace ranks #515 out of 782 companies for 3-Year RORE %. This places NeuroPace in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on NeuroPace and its competitors. NeuroPace's current 3-Year RORE % is -19.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.41, compared to a current price of $15.90 — trading 39.4% above its estimated fair value. The current 3-Year RORE % is -19.85. NeuroPace's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For NeuroPace (NPCE), the current 3-Year RORE % is -19.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $15.90 is trading 39.4% above its estimated GF Value™ of $11.41.
GuruFocus considers NeuroPace to be Significantly Overvalued.
Key valuation signals for NPCE:
3-Year RORE %: -19.85
GF Value™: $11.41 vs. price of $15.90 (39.4% above fair value)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
65GF Score
Get the complete analysis for NPCE
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 
